LifeSci Advisors Initiates Coverage On Rockwell Medical
LifeSci Advisors, LLC., a leading provider of investment research and
investor relations services in the life sciences sector, today announced
that it has initiated coverage on Rockwell Medical (NASDAQ: RMTI), a
LifeSci Advisors, LLC., a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage on Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease, and iron deficiency anemia. LifeSci Advisors’ 23-page Initiation Report contains a detailed discussion of Rockwell Medical’s current products and pipeline, including competitive positioning and growth opportunities. The report highlights recent achievements, short-term and long-term market dynamics, macroeconomic data indicators, and risks. A complete financial analysis including forecasts envisaging how Rockwell Medical may evolve as it enhances its product offerings and expands its operations. “Rockwell Medical is in the enviable position of having both an established, profitable base business and a potentially game-changing pipeline product in Soluble Ferric Pyrophosphate (SFP) to treat iron deficiency in ESRD patients,” commented Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Rockwell plans to initiate Phase 3 clinical studies in late 2010 and SFP could transform iron therapy by enhancing convenience and providing a more physiological iron delivery and better outcomes to hemodialysis patients suffering from anemia.” Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. LifeSci Advisors will also provide ongoing coverage and event-based research updates on Rockwell Medical as developments occur. The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and he worked as a medicinal chemist for several years at both Pfizer and Cytokinetics, prior to joining ThinkEquity.